Eden Research Share Discussion Threads

[investingisatrickygame] 20/10/2018 22:27

From Super's post 4719 under Human Health 2016

"TerpeneTech are currently undertaking human clinical trials and this is proceeding as expected. Additional work is ongoing with respect to the appointment of product development and launch partners, and much of this work will be informed by upcoming decisions about the regulatory paths to pursue in key markets."

This just about sums up TT, doesn't it>

. Doing clinical trials

. Appointing product development and launch partners

No money as Super keeps saying, they just seem to be a conduit from Eden to another, so maybe being opaque extends beyond Eden, in to TT and to...….?

Let's hope it becomes clear soon because you cannot get a rising share price and a happy shareholder base, let alone institutional investment if no one really understands your story because you choose to keep them in the dark.

[supersonico] 20/10/2018 22:09

AttyG,

Thanks for your detailed Answers, I guess time will tell if my delusional guesses have any basis in fact.
Either way progress is being made and news flow should pick up from here.



TerpeneTech Licence Agreement and Investment
Aug 2015

Given the progress that TerpeneTech is making and in order for Eden to take a bigger share of the potential future value that will be derived from this relationship, it was agreed that Eden should now take a strategic stake in TerpeneTech. In addition to the Investment made, Eden has the right to appoint a director to the Board of TerpeneTech and it shall do so in due course.

?

[attyg] 20/10/2018 18:45

Super, just sent you a pm

[attyg] 20/10/2018 18:26

Hmmm sorry, no idea who she is.

[attyg] 20/10/2018 18:24

They only wanted 4 companion products because that is all Teva were developing.
I would be amazed if Bayer and Eastman decided that the only use for Eden's IP is for four animal products and one nemanticide product.
No, I am expecting more from both and hopefully much more.
I have little doubt they are both working / trialing a number of products even as you read this. Why don't we hear from Eden that they are doing so? Well the market would not give any credence - they want to see da money, and Bayer and Eastman don't want the world to know their development plans.

[attyg] 20/10/2018 18:18

That is a very difficult one to answer and perhaps one which for the moment others are happy to keep below the radar.
I am sure we will find out eventually, but as I have trust in our board, I am happy to leave unanswered at this time.

[attyg] 20/10/2018 18:15

Well that has indeed been more than annoying.
Again as I don't subscribe to your proposition, TT delays due to undersesinmatimg the slowness of EU bureaucracy.
Bayer took over Teva, they had a lot to address, Eden's IP was simply not on the radar. Those at Teva who were promoting Eden IP were given new tasks, moved on etc. Bayer eventually rediscovered Eden's IP and are now pressing ahead.
One shouldn't overestimate large companies ableness effectiveness. They make as many mistakes as small companies - just different types of mistakes.
However, having woken up to the wide ranging array of possibilities which Eden IP can address, it could be that Bayer is running their slide rule over TT.
Don't know.

[attyg] 20/10/2018 18:06

Hmmm I don't really subscribe to your proposition.
I remain of the view that Bayer is not linked to TT - but could be wrong.

[attyg] 20/10/2018 18:04

There is something to hide, or you want people to think you are hiding something

[supersonico] 20/10/2018 15:05

Subject to Change and the art of The Muddle aka Keep it Opaque until Jan 2019.

Task = Blur Regulatory approval.

###### The process for regulatory clearances in both the US and the EU should now complete within the first half of 2018 enabling product sales in both regions during the second half of 2018.#########

###########We look forward to the UK product launch being the first of several in the EEA and eventually the US for both the head-lice product and other products, such as our naturally-derived under-arm deodorant, subject to any requisite regulatory approval."###############################
………;……̷0;……R30;……230;………

Quiz Questions

One only needs Smoke and Mirrors when...?

There is incongruence ..Because..?

We've had 4 years of Parallel delays because..?

TT do a lot of costly work but it cost them very little ..because..?

Bayer only wanted 4 Companion Animal products because..?

Prof Alice Roberts is a twitter follower of Eden because..?

[supersonico] 19/10/2018 18:29

AttyG,

Good to hear.

I expect them to have the whole Animal Health vertical...

...and for TT to either partner them or another big name for the Consumer/ Human health / biocides Products Vertical.

Eden 2013... Ground Zero = Bayer buy Teva.

Sean Smith joins a year later 2014 inspired by now larger opportunities and Ex Bayer Lykele van der Broek joins as Linkman 2018 ready for coordinated role out and commercial launch of Eden's revolutionary Technology in 2019-20. imo

May 2013

'The products being developed now by Bayer are a key part of the Company's sales strategy moving forward, with their intention to bring new, patented, environmentally and user-friendly solutions to the consumer pet market'.

'We look forward to the launch of product sales in the not too distant future and to working closely with Bayer to extend the sales opportunities for those products and to explore other areas of interest to Bayer, outside of animal health'.
……..

In fact I would not be surprised if we have news on every product in every vertical with a Sustaine TM commercial launch 2019, after all they have all been in pipeline / development for many years. I also expect the reinstatement of a cosmetics, flavours vertical.

EG;

Spider Mites and Whitefly May 2013

Eden is continuing discussions with various parties to license the rights for Spider Mites and Whitefly, the rights for which are currently available worldwide, excluding a small number of territories already covered in existing licences.

Trial work already done by Eden has shown good efficacy for these products and the intention is for prospective partners to take on the responsibility of further trials and registration.


eg May 2015

'Following the successful work with 3AEY, Sipcam is expanding its evaluations of Eden's technologies by conducting field trials on two new Eden products for the treatment of powdery mildew, which affects flowers and fruit, and apple scab during the course of 2015. These products are also based upon combinations of Eden's EU approved terpenes and its patented micro-encapsulation technology, GO-E™. It is anticipated that Sipcam will expand its evaluations in 2016 and potentially begin the product registration process under a new licence from Eden should the trials prove to be conclusive during the course of 2015'

Human health May 2014

In June 2013, Eden signed an agreement with NeoPharma Innovations Limited ("Neo") providing them with the exclusive rights to head-lice products. Since then, Neo has been very busy pursuing regulatory approval in both the European Union ("EU") and India, as well as progressing talks with interested distributors.

May 2014

'In addition to this exciting development, the Company has progressed with the development and commercialisation of products through its licensees and partners in other business sectors including human health, cosmetics, flavours and fragrances and animal health'


The Chronological evolution of TT headlice product which has cost TT approx. £80k . .What a bargain!!!


Human health Mar 2015

'Work is on-going to further develop and commercialise the Eden head-lice product. Other human health opportunities are being explored with potential licensing partners'.

TerpeneTech Licence Agreement and Investment Aug 2015.

Aug 2015

TerpeneTech has developed a head-lice product using Eden's GO-E™ encapsulation system and low-risk active ingredients. Based on recently concluded field trials, TerpeneTech's products deliver a high-level of efficacy in the direct treatment of head lice and their eggs. TerpeneTech is currently undertaking further human trials and product development in conjunction with leading scientific advisors and potential distribution partners.

Human health Aug 2016

In August we signed an exclusive licence agreement with TerpeneTech Limited granting them the right to use our technologies and intellectual property for the development of 'over the counter' head lice treatments for an upfront fee of £0.6m. This fee contributed to our licensing revenues. TerpeneTech are currently undertaking human clinical trials and this is proceeding as expected. Additional work is ongoing with respect to the appointment of product development and launch partners, and much of this work will be informed by upcoming decisions about the regulatory paths to pursue in key markets. Head lice treatment products can be approached differently (from a regulatory standpoint) in most of the world's largest markets, and TerpeneTech is taking care to ensure that the product registration strategy is sound and balances speed to market with product value and competitive differentiation.

Human health May 2017

Over the past year, TerpeneTech, which is an associate of Eden through Eden's shareholding of 29.9%, has undertaken a second successful round of clinical trials and has been preparing its regulatory submissions to both the US and EU authorities for approval of its head-lice treatment product.

Since the head-lice treatment product is expected to be a medical device, once the regulatory submission has been made and TerpeneTech has satisfied itself that it has met the regulatory requirements, it will be possible to commence sales of that product. It is expected that this submission will take place in the next few months.

In parallel, TerpeneTech has been negotiating with a number of different parties to distribute the head-lice product in the UK, initially, and then the rest of the EU and USA. It is expected that sales will commence this year.

Human health and biocides... Mar 2018

In 2016, TerpeneTech, which is an associate of Eden through Eden's shareholding of 29.9%, undertook a second successful round of clinical trials. Since then, the company has been preparing its regulatory submissions to both the US and EU authorities for approval of its head lice treatment product. These studies are essential and support product sales, as they are a pre-requisite to approval.

###### The process for regulatory clearances in both the US and the EU should now complete within the first half of 2018 enabling product sales in both regions during the second half of 2018.#########

In addition to completing the product trials, formulation stability testing and the required regulatory studies, TerpeneTech also concluded a commercial agreement appointing a channel partner for the UK market during the course of 2017. Further commercial agreements are pending in order to provide product distribution in additional key countries.

TerpeneTech is listed as a notified supplier of the active ingredient geraniol under the EU Biocidal Products Regulation. Sales of geraniol to third parties have increased year-on-year, and we are pleased with this progress. Eden derives a royalty payment from all sales of geraniol by TerpeneTech.

Further applications of Eden's technology remain in the development stage. However, TerpeneTech reports good progress with the development of its underarm deodorant product. This product will be marketed as a natural human deodorant product with superior, long-lasting performance derived, in part, from the use of Eden's microencapsulation system. There are currently advanced-stage discussions with potential commercial partners, and, assuming success with these, TerpeneTech anticipates product launches toward the end of 2018.

October 2018

Sales of the head-lice product into the distribution channel are expected to begin before the end of 2018 in the UK, where TerpeneTech's distribution channel partner has already been established, with commercial launch at the beginning of 2019. Sales will commence in other countries in the EEA once arrangements with additional distribution partners have been finalised. This is expected to take place during 2019.

###########We look forward to the UK product launch being the first of several in the EEA and eventually the US for both the head-lice product and other products, such as our naturally-derived under-arm deodorant, subject to any requisite regulatory approval." ############################### ………;……̷0;……R30;……230;……………………………;……̷0;……R30;……230;……………………………;….







.

[attyg] 19/10/2018 18:22

Re-examining TT's website, I see no reason for Bayer not to be commercialising companion pets products in Europe and indeed, worldwide.

[attyg] 19/10/2018 18:12

Sorry, super, I rechecked what I was looking at and realised everything is fine, nothing suspicious, so no need to send you a pm

[supersonico] 19/10/2018 14:09

AttyG,

The breadcrumbs I follow include;

The Prelims 2013 statement about possible opportunities post Teva that Bayer might be interested in. No further commentary regarding EU Companion Animals after this in any RNS, in fact EU Companion animals is only mentioned on Eden WWW page presentations .

TT have not from what I can tell invested anything like enough in product Development to match the commentary attributed to them by Lykele or Sean Smith where they describe the comparable regulatory and development processes for TT/Headlice as 'costly' and involving 'significant' recourses. There is a mismatch here imo.

Either TT working with another big player who is doing the heavy lifting and Duplicating without paying any stage payments or it's Bayer imo and as usual we are not seeing the big picture due to NDA's and possible coordinated global Brand launch etc. So were being told just enough to keep us invested until a Ducks are in line for the big day...maybe

With the investment Bayer have made into this area in Germany and New Zealand labs and their global reach I'm struggling to think of a reason why in 2013 they decided to take North America but Not EU..unless it was a Eden decision not to, but commercially that makes little sense to me, but they could very well have had their reasons for not giving a bigger chunk to Bayer.

Add in the stealth buying and No Holdings RNS and Eden not being noted in any Bayer Annual reports (That I've skimmed so could have missed) plus the Incongruence I have commented upon makes me believe that there is loads more here than meets the eye.

oh.. and lastly the difference in the IP protection narrative and the public perception snail speed that TT work at does not make sense to me..but I do know very little about these things and many of the wild assumptions I make could very well be due to my ignorance.

[investingisatrickygame] 19/10/2018 13:58

Super

Surely it is Bayer given the link you posted

[attyg] 19/10/2018 13:08

Hi super,

I see where you are coming from and you could be right.
I had previously thought it would be TT, however, it could indeed be Bayer.
I do not subscribe to the idea that Bayer have a clandestine or properly appropriate relationship with TT. I do not think they have any relationship with TT - but I could be proved wrong.

What is clear is that these markets are huge, Eden's IP is highly relevant and very much useable. It is all about priorities and directing scarce resources (human and money) to what is considered to be the quickest, most valuable, easiest etc.
I thought Eden had parcelled off a chunk of opportunity to TT for Herman etc to make hay with. Who knows, maybe Herman and Gary have indeed been lunching with Bayer.

I may send you a private email as I have deleted some stuff I had written.
Later

[supersonico] 19/10/2018 08:40

AttyG,

What's your thoughts on who might be involved with the EU Companion animal products?

Surely it's Bayer?

[attyg] 18/10/2018 18:46

Interesting, super.
Cheers

[supersonico] 18/10/2018 18:29

Dirk Ehle Bayer Animal Health Business


……………….

Bayer to Expand Animal Health Production in Germany


…………………

[supersonico] 18/10/2018 10:33

Biopesticides and biostimulants have become a hot topic in the agricultural sector in recent years. In the global biopesticide and biostimulant market, Europe is a relatively mature market, and many of its practices are worth learning from other countries. However, there are still some problems in the European biopesticide and biostimulant markets. Recently, AgroPages interviewed several representative biopesticide and biostimulant companies to discuss the current challenges and opportunities in the European market and how they responded to them

[supersonico] 17/10/2018 19:18

I would agree, Sipcam appear well placed, particularly as they are a significant shareholder and the scale to deliver but I would not rule out Eastman based on Global Footprint, regulatory pressure on Thiram , eggs in baskets and what they might also be able to offer Eden in the other parts of their business.

I don't think it's a simple decision.

[attyg] 17/10/2018 16:55

Strikes me that Sipcam is in pole position.
Obviously Sipcam Agro USA is not the biggest company in the States, but as they paid €600k back in June last year I guess they will effectively have first right of refusal on a number of territories/countries.
I also think Sipcam could be a great partner for the microencapsulation.
The relationship with Eden could transform Sipcam, never mind Eden.

Nevertheless, as you write, we need the right partner, will Sipcam stump up the dosh?
I think they will.

I reckon USA must be a priority for them and I daresay China, Argentina, Brazil and Chile also feature strongly.
I am thinking we will see a few RNSs regarding Sipcam over the lead up to Christmas.
They will probably pay across ~ £1m in one lump sum for all the territories, so as to mask what is agreed for each country.

While on licence fees, remember ~$500k to come from Bayer upon the animal product launches - before 31 Dec 2018.
Eastman launch Cedroz by 31 Dec, then what do we think - $1m - easy. Only downside is they have met all trialing and regulatory costs for a couple of years in all territories, so maybe no fee?
They still contracted to pay some fee - maybe see the size when the AR published.
But don't ya just feel the glow from Cedroz - yep, I do too.

I reckon we could also get a rabbit pulled out the hat with microencapsulation - big licence fee surely. Any microencapsulation deal, then, standback, we have lift off.

[investingisatrickygame] 17/10/2018 16:10

Who knows littlealbatross, maybe.

What I don't see is Mevalone being the biggest offering in Eden's stable. That has to be Sustaine TM as soon as Sipcam confirm co-encapsulation success.

However, what Mevalone does seem to offer is a one fits all solution to plant protection (as opposed to root protection). My understanding is the formulation does not change from grape protection to say. other fruit protection. I have asked our CEO this question an got that answer at the 2017 AGM. If anyone knows othersie, please correct me.

Therefore, once Mevalone is approved in America, I would assume that Eden has total control over whom they licence it to & for use on what product. That is a huge ongoing base income stream and the significance of the appointment of a distributor for Mevalone is the US and all of its extended licences cannot be underestimated.

Effectively, one distributor could control Mevalone throughout the USA for all target applications. Best get the right partner and not screw that up.

Attg or Super, any thought's on the above?

[littlealbatross2] 17/10/2018 15:58

So Canada legalizes cannabis....cannabis 'factories' to spring up across Canada.
A new market for Mevalone to control pests of this weed?

[supersonico] 17/10/2018 11:46

Interesting Figures Investing.

1.6 Dogs per household..that's higher than I would have guessed.